61
Seiwert Scott, Beigelman Leonid, Buckman Brad, Stoycheva Antitsa Dimitrova, Porter Steven B, Bradford Williamson Ziegler, Serebryany Vladimir: Novel macrocyclic inhibitors of hepatitis c virus replication. Intermune, Seiwert Scott, Beigelman Leonid, Buckman Brad, Stoycheva Antitsa Dimitrova, Porter Steven B, Bradford Williamson Ziegler, Serebryany Vladimir, Mallon Joseph J, November 26, 2009: WO/2009/142842 (25 worldwide citation)

The embodiments provide compounds of the general Formulae I, II, EI, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection an ...


62
Treadway Judith Lee: Use of glycogen phosphorylase inhibitors. Pfizer Prod, September 26, 2001: EP1136071-A2 (25 worldwide citation)

Individuals in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, can be treated prophylactically with a glycogen phosphorylase inhibitor; a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabet ...


63
Biller Scott A: Phosporus-containing squalene synthetase inhibitors, new intermediates and method.. Squibb & Sons, July 19, 1989: EP0324421-A2 (25 worldwide citation)

Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have the structure wherein Q is or a bond; Z is -(CH2)n- or -(CH2)p-CH=CH-(CH2)m-, wherein n is 1 to 5; p is 0, 1 or 2; m is 0, 1 or 2; R, R and R are the same or different ...


64

65
Bacterial strain and genome of bifidobacterium. Nestle, July 31, 2002: EP1227152-A1 (24 worldwide citation)

The present invention pertains to a novel microorganism of the genus Bifidobacterium longum, in particular to its genomic sequence and the nucleotide sequences encoding polypeptides of Bifidobacterium NCC2705 (CNCM I-2618), which are secreted or specific or which are involved in the metabolism, in t ...


66
Gibbs Jackson B, Garsky Victor M, Rands Elaine, Pompliano David L: Non-substrate peptide inhibitors of farnesyl protein transferase.. Merck & Co, January 20, 1993: EP0523873-A1 (24 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


67
Rigbi Meir, Jackson Craig: Bovine factor xa inhibiting factor and pharmaceutical compositions containing the same.. Yissum Res Dev Co, American Nat Red Cross, January 31, 1990: EP0352903-A2 (24 worldwide citation)

An anticoagulant/modulator factor isolated from the saliva of the medicinal leech Hirudo medicinalis, specifically inhibiting bovine Xa factor but not inhibiting bovine thrombin.


68

69
Tabor Stanley, Richardson Charles C: T7 dna polymerase.. Harvard College, April 27, 1988: EP0265293-A2 (24 worldwide citation)

This invention relates to T7-type DNA polymerases and methods for using them including a method for determining the nucleotide base sequence of a DNA molecule, comprising annealing said DNA molecule with a primer molecule able to hybridize to said DNA molecule; incubating separate portions of the an ...


70
Dickens Jonathan Philip, Donald David Keith, Kneen Geoffrey, Mckay William Roger: Hydroxamic acid based collagenase inhibitors.. Searle & Co, March 18, 1987: EP0214639-A2 (24 worldwide citation)

This invention relates to a novel class of hydroxamic acid based collagenase inhibitor derivatives of the formula wherein R is C1-C6 alkyl; R is C1-C6 alkyl, benzyl, hydroxybenzyl, benzyloxybenzyl, (C1-C6 alkoxy)benzyl, or benzyloxy(C1-C6 alkyl); a is a chiral center with optional R or S stereochemi ...